相似文献
1
Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B.
Sci Transl Med. 2010 Jan 20;2(15):15ra6. doi: 10.1126/scitranslmed.3000331.
2
Discovery of imidazo[2,1-b]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents.
J Med Chem. 2015 Mar 26;58(6):2764-78. doi: 10.1021/jm501934n. Epub 2015 Mar 11.
3
Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B.
Antimicrob Agents Chemother. 2014 Jun;58(6):3399-410. doi: 10.1128/AAC.00113-14. Epub 2014 Apr 7.
4
A small molecule inhibits HCV replication and alters NS4B's subcellular distribution.
Antiviral Res. 2010 Jul;87(1):1-8. doi: 10.1016/j.antiviral.2010.03.013. Epub 2010 Apr 2.
5
Aminoterminal amphipathic α-helix AH1 of hepatitis C virus nonstructural protein 4B possesses a dual role in RNA replication and virus production.
PLoS Pathog. 2014 Nov 13;10(10):e1004501. doi: 10.1371/journal.ppat.1004501. eCollection 2014 Oct.
6
Hepatitis C replication inhibitors that target the viral NS4B protein.
J Med Chem. 2014 Mar 13;57(5):2107-20. doi: 10.1021/jm400125h. Epub 2013 Apr 19.
7
Glycine Zipper Motifs in Hepatitis C Virus Nonstructural Protein 4B Are Required for the Establishment of Viral Replication Organelles.
J Virol. 2018 Jan 30;92(4). doi: 10.1128/JVI.01890-17. Print 2018 Feb 15.
8
Interaction networks of hepatitis C virus NS4B: implications for antiviral therapy.
Cell Microbiol. 2012 Jul;14(7):994-1002. doi: 10.1111/j.1462-5822.2012.01773.x. Epub 2012 Mar 5.
9
In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
Antimicrob Agents Chemother. 2014 Aug;58(8):4431-42. doi: 10.1128/AAC.02777-13. Epub 2014 May 27.
10
Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
Curr Opin Virol. 2013 Oct;3(5):514-20. doi: 10.1016/j.coviro.2013.06.014. Epub 2013 Jul 27.
引用本文的文献
1
Identification of a Proline-Kinked Amphipathic α-Helix Downstream from the Methyltransferase Domain of a Potexvirus Replicase and Its Role in Virus Replication and Perinuclear Complex Formation.
J Virol. 2021 Sep 27;95(20):e0190620. doi: 10.1128/JVI.01906-20. Epub 2021 Aug 4.
2
Trimerization of the N-Terminal Tail of Zika Virus NS4A Protein: A Potential In Vitro Antiviral Screening Assay.
Membranes (Basel). 2021 Apr 30;11(5):335. doi: 10.3390/membranes11050335.
3
Preclinical evaluation of Amphihevir, a first-in-class clinical Hepatitis C virus NS4B inhibitor.
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01237-19. Epub 2019 Sep 16.
4
Suppression of Hepatitis C Virus Genome Replication and Particle Production by a Novel Diacylglycerol Acyltransferases Inhibitor.
Molecules. 2018 Aug 20;23(8):2083. doi: 10.3390/molecules23082083.
5
Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase.
Br J Pharmacol. 2016 Jan;173(1):191-211. doi: 10.1111/bph.13358. Epub 2015 Nov 25.
6
Chronic Hepatitis C Infection in Children: Current Treatment and New Therapies.
J Clin Transl Hepatol. 2015 Mar;3(1):36-41. doi: 10.14218/JCTH.2014.00036. Epub 2015 Mar 15.
7
Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.
Antimicrob Agents Chemother. 2015 Oct;59(10):6539-50. doi: 10.1128/AAC.00813-15. Epub 2015 Aug 10.
8
Interaction between the NS4B amphipathic helix, AH2, and charged lipid headgroups alters membrane morphology and AH2 oligomeric state--Implications for the Hepatitis C virus life cycle.
Biochim Biophys Acta. 2015 Aug;1848(8):1671-7. doi: 10.1016/j.bbamem.2015.04.015. Epub 2015 May 2.
9
Encoded library technology screening of hepatitis C virus NS4B yields a small-molecule compound series with in vitro replicon activity.
Antimicrob Agents Chemother. 2015;59(6):3450-9. doi: 10.1128/AAC.00070-15. Epub 2015 Mar 30.
10
The interaction between the hepatitis C proteins NS4B and NS5A is involved in viral replication.
Virology. 2015 Jan 15;475:139-49. doi: 10.1016/j.virol.2014.10.021. Epub 2014 Dec 2.
本文引用的文献
1
Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection.
Expert Opin Ther Pat. 2009 Feb;19(2):145-64. doi: 10.1517/13543770802672598.
2
Identification of a novel determinant for membrane association in hepatitis C virus nonstructural protein 4B.
J Virol. 2009 Jun;83(12):6257-68. doi: 10.1128/JVI.02663-08. Epub 2009 Apr 8.
3
New therapies for hepatitis C virus infection.
Clin Infect Dis. 2009 Feb 1;48(3):313-20. doi: 10.1086/595848.
4
Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis.
Nat Biotechnol. 2008 Sep;26(9):1019-27. doi: 10.1038/nbt.1490.
5
The way forward in HCV treatment--finding the right path.
Nat Rev Drug Discov. 2007 Dec;6(12):991-1000. doi: 10.1038/nrd2411.
6
A Rab-GAP TBC domain protein binds hepatitis C virus NS5A and mediates viral replication.
J Virol. 2007 Oct;81(20):11096-105. doi: 10.1128/JVI.01249-07. Epub 2007 Aug 8.
7
Replication of hepatitis C virus.
Nat Rev Microbiol. 2007 Jun;5(6):453-63. doi: 10.1038/nrmicro1645. Epub 2007 May 8.
8
Dual topology of the processed hepatitis C virus protein NS4B is influenced by the NS5A protein.
J Gen Virol. 2006 Nov;87(Pt 11):3263-3272. doi: 10.1099/vir.0.82211-0.
9
Palmitoylation and polymerization of hepatitis C virus NS4B protein.
J Virol. 2006 Jun;80(12):6013-23. doi: 10.1128/JVI.00053-06.
10
Global epidemiology of hepatitis C virus infection.
Lancet Infect Dis. 2005 Sep;5(9):558-67. doi: 10.1016/S1473-3099(05)70216-4.
Zotero 插件